1. Home
  2. DAWN vs ELME Comparison

DAWN vs ELME Comparison

Compare DAWN & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • ELME
  • Stock Information
  • Founded
  • DAWN 2018
  • ELME 1960
  • Country
  • DAWN United States
  • ELME United States
  • Employees
  • DAWN N/A
  • ELME N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • ELME Real Estate Investment Trusts
  • Sector
  • DAWN Health Care
  • ELME Real Estate
  • Exchange
  • DAWN Nasdaq
  • ELME Nasdaq
  • Market Cap
  • DAWN 1.6B
  • ELME 1.5B
  • IPO Year
  • DAWN 2021
  • ELME N/A
  • Fundamental
  • Price
  • DAWN $13.34
  • ELME $15.87
  • Analyst Decision
  • DAWN Strong Buy
  • ELME Hold
  • Analyst Count
  • DAWN 7
  • ELME 5
  • Target Price
  • DAWN $36.17
  • ELME $17.50
  • AVG Volume (30 Days)
  • DAWN 1.3M
  • ELME 558.3K
  • Earning Date
  • DAWN 10-30-2024
  • ELME 11-04-2024
  • Dividend Yield
  • DAWN N/A
  • ELME 4.53%
  • EPS Growth
  • DAWN N/A
  • ELME N/A
  • EPS
  • DAWN N/A
  • ELME N/A
  • Revenue
  • DAWN $101,953,000.00
  • ELME $239,523,000.00
  • Revenue This Year
  • DAWN N/A
  • ELME N/A
  • Revenue Next Year
  • DAWN $44.21
  • ELME $2.78
  • P/E Ratio
  • DAWN N/A
  • ELME N/A
  • Revenue Growth
  • DAWN N/A
  • ELME 6.62
  • 52 Week Low
  • DAWN $11.30
  • ELME $12.74
  • 52 Week High
  • DAWN $18.07
  • ELME $18.49
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 38.64
  • ELME 33.80
  • Support Level
  • DAWN $12.86
  • ELME $15.56
  • Resistance Level
  • DAWN $13.71
  • ELME $17.89
  • Average True Range (ATR)
  • DAWN 0.77
  • ELME 0.43
  • MACD
  • DAWN -0.25
  • ELME -0.14
  • Stochastic Oscillator
  • DAWN 12.24
  • ELME 13.09

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located primarily near major transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's largest tenants are banking, consulting, law, and financial services firms.

Share on Social Networks: